Dupixent FDA approved as the first biologic medicine for young children with chronic spontaneous urticaria

On April 22, Sanofi and Regeneron announced that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) to expand its use for the treatment of children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine (H1AH) treatment. Previous approval was for adults and adolescents aged 12 years and older.

Read the press release:
Sanofi press release
Dupixent(dupilumab)-Prescription Information:
Dupixent-PI

Icotyde™(icotrokinra)-FDA Approval

On march 18 Johnson & Johnson announced that the U.S Food and Drug Administration(FDA) has approved Icotyde™(icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.

Things to note with new Icotyde™(icotrokinra) therapy:

- One daily unique dose of 200mg
- Tuberculosis test is recommended but not required. Left to the physician's discretion
- Bridge available for commercially insured patients

Read the press release:
J&J press release
Icotyde™(icotrokinra)-Prescription Information:
Icotyde-PI

ACDOSA participates in Dallas ACBC round up 2026

We were invited to participate in Dallas, Texas round up on march 7th 2026.
We really appreciate the support that Access Coordinator Boot Camp and Biomazze have provided for our goal to extend the benefits of ACDOSA to Access coordinators throughout Texas and the rest of the United States.
It was a great experience to learn from others and to present ACDOSA, showing what it can offer to improve our daily practice.
Diana G

A new Resources section organizes reference materials including the Vaccine Reference guide and Shelf Life page.

A dedicated Resources section now groups all reference materials in one place. This includes the Shelf Life page (previously in the main navigation) and our new Vaccines reference page.

The new Vaccines reference page lists vaccines commonly encountered in biologic therapy management. Each vaccine entry shows whether it's live or inactivated and the FDA-approved age range.

Live vaccines are contraindicated during biologic therapy. Inactivated vaccines are safe. Having this information in one place makes it easier to coordinate vaccination timing with treatment.

The page includes a filter to quickly find specific vaccines.

New specialty pharmacy for Sun Pharma pharmacy dispensing services (Ilumya, Odomzo, and Leqselvi)

Effective 01/01/2026, pharmacy services for Sun Pharma products Ilumya, Odomzo, and Leqselvi will be transferred to ConnectiveRx Pharmacy powered by Zeal Specialty Pharmacy.

What to expect:

• Refill requests, clarification calls, or prior authorization follow-ups from ConnectiveRx Pharmacy powered by Zeal Specialty Pharmacy, but no new prescriptions are required.


• Patients will continue to receive medication deliveries on their established schedule without interruption because they transferred patient profiles, active prescriptions, prior authorizations, and co-pay assistance information.


• Communication to affected patients is being sent separately to ensure that they are aware of the change and have the updated contact information.

Pharmacy contact information:
ConnectiveRx Pharmacy powered by Zeal Specialty Pharmacy
Phone: 888-412-9325 (ZEAL) option 2 for a verbal order
Fax: 877-329-9325

A new Shelf Life & Storage section is now available on the site.

A new Shelf Life & Storage section has been added to the site, covering shelf life and storage information for dermatology biologic medications.

You'll find:

• Room temperature allowances (including differences between pens, prefilled syringes, and vials when applicable)


• Latex in Needle/Vial Cover information


• A dropdown filter to quickly find specific medications by name or active ingredient

This makes it easier to quickly reference storage requirements and latex allergy considerations.

The dermatology dosing tool has been updated with additional medications and improved readability.

Fifteen new medications have been added to the dermatology dosing tool (14 oral and 1 injectable), bringing the total to 48 medications.
The text size for loading and maintenance dose results has also been slightly increased to improve readability.

We’ve updated the dermatology dosing tool.

New medications have been added, and active ingredients are now included for all medications in the dermatology dosing tool.
This brings the total to 33 medications available.

For faster and more efficient interaction, the medication selection field in the tool now displays an “X” button when a selection is made. This allows users to quickly clear the selection from the filter box without manually deleting it using the keyboard.